David Fellows's most recent trade in Terns Pharmaceuticals Inc was a trade of 45,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Terns Pharma Inc | David Fellows | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2026 | 45,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Terns Pharma Inc | David Fellows | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2026 | 32,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Terns Pharma Inc | David Fellows | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2026 | 32,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Terns Pharma Inc | David Fellows | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2026 | 32,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Terns Pharma Inc | David Fellows | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2026 | 28,475 | 0 | - | - | Stock Option (Right to Buy) | |
| Terns Pharma Inc | David Fellows | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2026 | 22,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Terns Pharma Inc | David Fellows | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2026 | 18,650 | 0 | - | - | Stock Option (Right to Buy) | |
| Terns Pharma Inc | David Fellows | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2026 | 8,183 | 0 | - | - | Stock Option (Right to Buy) | |
| Terns Pharma Inc | David Fellows | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2026 | 2,828 | 0 | - | - | Stock Option (Right to Buy) | |
| Terns Pharma Inc | David Fellows | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2026 | 2,828 | 2,828 | - | - | Stock Option (Right to Buy) | |
| Terns Pharma Inc | David Fellows | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Terns Pharma Inc | David Fellows | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 18,650 | 18,650 | - | - | Stock Option (Right to Buy) | |
| Terns Pharma Inc | David Fellows | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 8,183 | 8,183 | - | - | Stock Option (Right to Buy) | |
| Terns Pharma Inc | David Fellows | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| Terns Pharma Inc | David Fellows | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| Terns Pharma Inc | David Fellows | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2021 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) |